Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatment. Neither Cohort-1 nor Cohort-2 are open to patients with a partial response after the immediate prior treatment (including salvage therapy before autologous or allogeneic transplantation); such patients would become eligible only upon subsequent progression.

• A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab … Recruitment ended
  2024-520123-83-01 4 2020-02-11

Showing 1–1 of 1 trials